ID   MADD_HUMAN              Reviewed;        1647 AA.
AC   Q8WXG6; A8K8S7; B5MEE5; D3DQR4; O15065; O15293; Q15732; Q15741; Q8IWD7;
AC   Q8WXG3; Q8WXG4; Q8WXG5; Q8WZ63;
DT   20-FEB-2007, integrated into UniProtKB/Swiss-Prot.
DT   20-FEB-2007, sequence version 2.
DT   28-JUN-2023, entry version 155.
DE   RecName: Full=MAP kinase-activating death domain protein;
DE   AltName: Full=Differentially expressed in normal and neoplastic cells;
DE   AltName: Full=Insulinoma glucagonoma clone 20;
DE   AltName: Full=Rab3 GDP/GTP exchange factor;
DE            Short=RabGEF {ECO:0000305};
DE   AltName: Full=Rab3 GDP/GTP exchange protein {ECO:0000305};
DE            Short=Rab3GEP {ECO:0000305};
GN   Name=MADD {ECO:0000312|EMBL:AAB57735.1, ECO:0000312|HGNC:HGNC:6766};
GN   Synonyms=DENN {ECO:0000312|EMBL:AAD12154.1}, IG20
GN   {ECO:0000312|EMBL:AAL40265.1}, KIAA0358 {ECO:0000312|EMBL:BAA20814.2};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1] {ECO:0000305, ECO:0000312|EMBL:AAD12154.1}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 3 AND 4), SUBCELLULAR LOCATION, TISSUE
RP   SPECIFICITY, AND DEVELOPMENTAL STAGE.
RC   TISSUE=Fetal liver {ECO:0000312|EMBL:AAD12154.1};
RX   PubMed=8988362; DOI=10.3109/10425179609020873;
RA   Chow V.T.K., Lee S.S.;
RT   "DENN, a novel human gene differentially expressed in normal and neoplastic
RT   cells.";
RL   DNA Seq. 6:263-273(1996).
RN   [2] {ECO:0000305, ECO:0000312|EMBL:AAB57735.1}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), FUNCTION, INTERACTION WITH
RP   TNFRSF1A, VARIANT MET-751, AND TISSUE SPECIFICITY.
RX   PubMed=9115275; DOI=10.1074/jbc.272.18.12069;
RA   Schievella A.R., Chen J.H., Graham J.R., Lin L.-L.;
RT   "MADD, a novel death domain protein that interacts with the type 1 tumor
RT   necrosis factor receptor and activates mitogen-activated protein kinase.";
RL   J. Biol. Chem. 272:12069-12075(1997).
RN   [3] {ECO:0000305, ECO:0000312|EMBL:AAD12154.1}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 3 AND 4), AND TISSUE SPECIFICITY.
RC   TISSUE=Liver {ECO:0000312|EMBL:AAD12154.1};
RX   PubMed=9796103; DOI=10.1139/g98-050;
RA   Chow V.T.K., Lim K.M., Lim D.;
RT   "The human DENN gene: genomic organization, alternative splicing, and
RT   localization to chromosome 11p11.21-p11.22.";
RL   Genome 41:543-552(1998).
RN   [4] {ECO:0000305, ECO:0000312|EMBL:AAL40265.1}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 4; 5 AND 6), FUNCTION, AND
RP   INTERACTION WITH TNFRSF1A.
RC   TISSUE=Insulinoma {ECO:0000269|PubMed:11577081};
RX   PubMed=11577081; DOI=10.1074/jbc.m104835200;
RA   Al-Zoubi A.M., Efimova E.V., Kaithamana S., Martinez O.,
RA   El-Azami El-Idrissi M., Dogan R.E., Prabhakar B.S.;
RT   "Contrasting effects of IG20 and its splice isoforms, MADD and DENN-SV, on
RT   tumor necrosis factor alpha-induced apoptosis and activation of caspase-8
RT   and -3.";
RL   J. Biol. Chem. 276:47202-47211(2001).
RN   [5] {ECO:0000305, ECO:0000312|EMBL:BAA20814.2}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 7).
RC   TISSUE=Brain {ECO:0000312|EMBL:BAA20814.2};
RX   PubMed=9205841; DOI=10.1093/dnares/4.2.141;
RA   Nagase T., Ishikawa K., Nakajima D., Ohira M., Seki N., Miyajima N.,
RA   Tanaka A., Kotani H., Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. VII. The
RT   complete sequences of 100 new cDNA clones from brain which can code for
RT   large proteins in vitro.";
RL   DNA Res. 4:141-150(1997).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 8).
RC   TISSUE=Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F., Bloom T.,
RA   Bruford E., Chang J.L., Cuomo C.A., Eichler E., FitzGerald M.G.,
RA   Jaffe D.B., LaButti K., Nicol R., Park H.-S., Seaman C., Sougnez C.,
RA   Yang X., Zimmer A.R., Zody M.C., Birren B.W., Nusbaum C., Fujiyama A.,
RA   Hattori M., Rogers J., Lander E.S., Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9] {ECO:0000305, ECO:0000312|EMBL:AAH40484.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 5), AND VARIANTS THR-696;
RP   GLY-968 AND PHE-1040.
RC   TISSUE=Testis {ECO:0000312|EMBL:AAH40484.1};
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   INTERACTION WITH PIDD1.
RX   PubMed=10825539; DOI=10.1016/s0167-4838(00)00029-7;
RA   Telliez J.-B., Bean K.M., Lin L.-L.;
RT   "LRDD, a novel leucine rich repeat and death domain containing protein.";
RL   Biochim. Biophys. Acta 1478:280-288(2000).
RN   [11] {ECO:0000305}
RP   ALTERNATIVE SPLICING, AND TISSUE SPECIFICITY.
RX   PubMed=14716293; DOI=10.1038/sj.onc.1207210;
RA   Efimova E.V., Al-Zoubi A.M., Martinez O., Kaithamana S., Lu S., Arima T.,
RA   Prabhakar B.S.;
RT   "IG20, in contrast to DENN-SV, (MADD splice variants) suppresses tumor cell
RT   survival, and enhances their susceptibility to apoptosis and cancer
RT   drugs.";
RL   Oncogene 23:1076-1087(2004).
RN   [12]
RP   INTERACTION WITH YWHAZ.
RX   PubMed=16959763; DOI=10.1074/mcp.m600147-mcp200;
RA   Angrand P.O., Segura I., Voelkel P., Ghidelli S., Terry R., Brajenovic M.,
RA   Vintersten K., Klein R., Superti-Furga G., Drewes G., Kuster B.,
RA   Bouwmeester T., Acker-Palmer A.;
RT   "Transgenic mouse proteomics identifies new 14-3-3-associated proteins
RT   involved in cytoskeletal rearrangements and cell signaling.";
RL   Mol. Cell. Proteomics 5:2211-2227(2006).
RN   [13]
RP   FUNCTION.
RX   PubMed=18559336; DOI=10.1074/jbc.m804134200;
RA   Figueiredo A.C., Wasmeier C., Tarafder A.K., Ramalho J.S., Baron R.A.,
RA   Seabra M.C.;
RT   "Rab3GEP is the non-redundant guanine nucleotide exchange factor for Rab27a
RT   in melanocytes.";
RL   J. Biol. Chem. 283:23209-23216(2008).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-818; SER-820 AND SER-921, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [18]
RP   FUNCTION AS GUANYL-NUCLEOTIDE EXCHANGE FACTOR.
RX   PubMed=20937701; DOI=10.1083/jcb.201008051;
RA   Yoshimura S., Gerondopoulos A., Linford A., Rigden D.J., Barr F.A.;
RT   "Family-wide characterization of the DENN domain Rab GDP-GTP exchange
RT   factors.";
RL   J. Cell Biol. 191:367-381(2010).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-156; SER-692; SER-858;
RP   SER-862; SER-916; SER-921; SER-1059; THR-1237; SER-1239 AND SER-1270, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [22]
RP   INVOLVEMENT IN NEDDISH, VARIANTS NEDDISH HIS-198 AND ARG-327--1647-SER DEL,
RP   AND VARIANT ARG-1040.
RX   PubMed=28940097; DOI=10.1007/s00439-017-1843-2;
RA   Anazi S., Maddirevula S., Salpietro V., Asi Y.T., Alsahli S., Alhashem A.,
RA   Shamseldin H.E., AlZahrani F., Patel N., Ibrahim N., Abdulwahab F.M.,
RA   Hashem M., Alhashmi N., Al Murshedi F., Al Kindy A., Alshaer A.,
RA   Rumayyan A., Al Tala S., Kurdi W., Alsaman A., Alasmari A., Banu S.,
RA   Sultan T., Saleh M.M., Alkuraya H., Salih M.A., Aldhalaan H., Ben-Omran T.,
RA   Al Musafri F., Ali R., Suleiman J., Tabarki B., El-Hattab A.W., Bupp C.,
RA   Alfadhel M., Al Tassan N., Monies D., Arold S.T., Abouelhoda M.,
RA   Lashley T., Houlden H., Faqeih E., Alkuraya F.S.;
RT   "Expanding the genetic heterogeneity of intellectual disability.";
RL   Hum. Genet. 136:1419-1429(2017).
RN   [23]
RP   ERRATUM OF PUBMED:28940097.
RX   PubMed=29288388; DOI=10.1007/s00439-017-1859-7;
RA   Anazi S., Maddirevula S., Salpietro V., Asi Y.T., Alsahli S., Alhashem A.,
RA   Shamseldin H.E., AlZahrani F., Patel N., Ibrahim N., Abdulwahab F.M.,
RA   Hashem M., Alhashmi N., Al Murshedi F., Al Kindy A., Alshaer A.,
RA   Rumayyan A., Al Tala S., Kurdi W., Alsaman A., Alasmari A., Banu S.,
RA   Sultan T., Saleh M.M., Alkuraya H., Salih M.A., Aldhalaan H., Ben-Omran T.,
RA   Al Musafri F., Ali R., Suleiman J., Tabarki B., El-Hattab A.W., Bupp C.,
RA   Alfadhel M., Al Tassan N., Monies D., Arold S.T., Abouelhoda M.,
RA   Lashley T., Houlden H., Faqeih E., Alkuraya F.S.;
RT   "Correction to: Expanding the genetic heterogeneity of intellectual
RT   disability.";
RL   Hum. Genet. 137:105-109(2018).
RN   [24]
RP   INVOLVEMENT IN DEEAH, VARIANTS DEEAH ARG-216--1647-SER DEL; PHE-257;
RP   VAL-305; ARG-327--1647-SER DEL; LEU-372; ARG-1040 AND TRP-1431--1647-SER
RP   DEL, VARIANTS NEDDISH PRO-346; LEU-354; PRO-945; SER-1213--1647-SER DEL;
RP   SER-1283; ARG-1318 AND ARG-1532--1647-SER DEL, CHARACTERIZATION OF VARIANTS
RP   DEEAH VAL-305; ARG-1040, AND FUNCTION.
RX   PubMed=32761064; DOI=10.1093/brain/awaa204;
RG   Undiagnosed Diseases Network;
RA   Schneeberger P.E., Kortuem F., Korenke G.C., Alawi M., Santer R., Woidy M.,
RA   Buhas D., Fox S., Juusola J., Alfadhel M., Webb B.D., Coci E.G.,
RA   Abou Jamra R., Siekmeyer M., Biskup S., Heller C., Maier E.M.,
RA   Javaher-Haghighi P., Bedeschi M.F., Ajmone P.F., Iascone M., Peeters H.,
RA   Ballon K., Jaeken J., Rodriguez Alonso A., Palomares-Bralo M.,
RA   Santos-Simarro F., Meuwissen M.E.C., Beysen D., Kooy R.F., Houlden H.,
RA   Murphy D., Doosti M., Karimiani E.G., Mojarrad M., Maroofian R.,
RA   Noskova L., Kmoch S., Honzik T., Cope H., Sanchez-Valle A., Gelb B.D.,
RA   Kurth I., Hempel M., Kutsche K.;
RT   "Biallelic MADD variants cause a phenotypic spectrum ranging from
RT   developmental delay to a multisystem disorder.";
RL   Brain 143:2437-2453(2020).
CC   -!- FUNCTION: Guanyl-nucleotide exchange factor that regulates small
CC       GTPases of the Rab family (PubMed:20937701, PubMed:18559336). Converts
CC       GDP-bound inactive form of RAB27A and RAB27B to the GTP-bound active
CC       forms (PubMed:20937701, PubMed:18559336). Converts GDP-bound inactive
CC       form of RAB3A, RAB3C and RAB3D to the GTP-bound active forms, GTPases
CC       involved in synaptic vesicle exocytosis and vesicle secretion (By
CC       similarity). Plays a role in synaptic vesicle formation and in vesicle
CC       trafficking at the neuromuscular junction (By similarity). Involved in
CC       up-regulating a post-docking step of synaptic exocytosis in central
CC       synapses (By similarity). Probably by binding to the motor proteins
CC       KIF1B and KIF1A, mediates motor-dependent transport of GTP-RAB3A-
CC       positive vesicles to the presynaptic nerve terminals (By similarity).
CC       Plays a role in TNFA-mediated activation of the MAPK pathway, including
CC       ERK1/2 (PubMed:32761064). May link TNFRSF1A with MAP kinase activation
CC       (PubMed:9115275). May be involved in the regulation of TNFA-induced
CC       apoptosis (PubMed:11577081, PubMed:32761064).
CC       {ECO:0000250|UniProtKB:O08873, ECO:0000250|UniProtKB:Q80U28,
CC       ECO:0000269|PubMed:11577081, ECO:0000269|PubMed:18559336,
CC       ECO:0000269|PubMed:20937701, ECO:0000269|PubMed:32761064,
CC       ECO:0000269|PubMed:9115275}.
CC   -!- SUBUNIT: Interacts (via death domain) with TNFRSF1A (via death domain)
CC       (PubMed:9115275, PubMed:11577081). Interacts with PIDD1
CC       (PubMed:10825539). Interacts with YWHAZ (PubMed:16959763). Interacts
CC       (via death domain) with KIF1B (By similarity). Interacts with KIF1A (By
CC       similarity). Interacts (via uDENN domain) with RAB3A, RAB3B, RAB3C and
CC       RAB3D; the GTP-bound form of the Rab proteins is preferred for
CC       interaction (By similarity). {ECO:0000250|UniProtKB:Q80U28,
CC       ECO:0000269|PubMed:10825539, ECO:0000269|PubMed:11577081,
CC       ECO:0000269|PubMed:16959763, ECO:0000269|PubMed:9115275}.
CC   -!- INTERACTION:
CC       Q8WXG6; Q9NUX5: POT1; NbExp=2; IntAct=EBI-310528, EBI-752420;
CC       Q8WXG6; Q16849: PTPRN; NbExp=4; IntAct=EBI-310528, EBI-728153;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:8988362}.
CC       Cytoplasm {ECO:0000269|PubMed:8988362}. Cell projection, axon
CC       {ECO:0000250|UniProtKB:Q80U28}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=8;
CC       Name=1 {ECO:0000269|PubMed:11577081}; Synonyms=IG20
CC       {ECO:0000269|PubMed:11577081}, IG20-FL {ECO:0000269|PubMed:14716293};
CC         IsoId=Q8WXG6-1; Sequence=Displayed;
CC       Name=2 {ECO:0000269|PubMed:11577081}; Synonyms=IG20
CC       {ECO:0000269|PubMed:14716293}, IG20-PA {ECO:0000269|PubMed:11577081},
CC       IG20-PASV {ECO:0000269|PubMed:11577081};
CC         IsoId=Q8WXG6-2; Sequence=VSP_052295, VSP_052296;
CC       Name=3 {ECO:0000269|PubMed:8988362, ECO:0000269|PubMed:9115275,
CC       ECO:0000269|PubMed:9796103}; Synonyms=DENN {ECO:0000269|PubMed:8988362,
CC       ECO:0000269|PubMed:9796103}, IG20-SV1 {ECO:0000269|PubMed:14716293},
CC       MADD {ECO:0000269|PubMed:9115275};
CC         IsoId=Q8WXG6-3; Sequence=VSP_052294, VSP_052295, VSP_055676,
CC                                  VSP_052296;
CC       Name=4 {ECO:0000269|PubMed:11577081, ECO:0000269|PubMed:8988362,
CC       ECO:0000269|PubMed:9796103}; Synonyms=IG20-SV2
CC       {ECO:0000269|PubMed:11577081};
CC         IsoId=Q8WXG6-4; Sequence=VSP_052293, VSP_052295, VSP_052296;
CC       Name=5 {ECO:0000269|PubMed:11577081, ECO:0000269|PubMed:15489334};
CC       Synonyms=DENN-SV {ECO:0000269|PubMed:15489334}, IG20-SV3
CC       {ECO:0000269|PubMed:11577081};
CC         IsoId=Q8WXG6-5; Sequence=VSP_052293, VSP_052294, VSP_052295,
CC                                  VSP_052296;
CC       Name=6 {ECO:0000269|PubMed:11577081}; Synonyms=IG20-SV4
CC       {ECO:0000269|PubMed:11577081};
CC         IsoId=Q8WXG6-6; Sequence=VSP_052293, VSP_052294, VSP_052295,
CC                                  VSP_052296, VSP_052297, VSP_052298;
CC       Name=7 {ECO:0000269|PubMed:9205841}; Synonyms=KIAA0358
CC       {ECO:0000303|PubMed:32761064};
CC         IsoId=Q8WXG6-7; Sequence=VSP_052297, VSP_052298;
CC       Name=8;
CC         IsoId=Q8WXG6-8; Sequence=VSP_052293, VSP_052294, VSP_052295,
CC                                  VSP_044848, VSP_052296;
CC   -!- TISSUE SPECIFICITY: Expressed in testis, ovary, brain and heart
CC       (PubMed:8988362). Expressed in spleen, thymus, prostate, testis, ovary,
CC       small instestine and colon (PubMed:9115275). Expressed in liver
CC       (PubMed:9796103). {ECO:0000269|PubMed:8988362,
CC       ECO:0000269|PubMed:9115275, ECO:0000269|PubMed:9796103}.
CC   -!- TISSUE SPECIFICITY: [Isoform 1]: Not detected in the brain, breast,
CC       kidney, lung, ovary, pancreas, testis, uterus, stomach and thyroid.
CC       {ECO:0000269|PubMed:14716293}.
CC   -!- TISSUE SPECIFICITY: [Isoform 2]: Expressed in the brain, breast,
CC       kidney, lung, ovary, pancreas, testis, uterus, stomach and thyroid.
CC       {ECO:0000269|PubMed:14716293}.
CC   -!- TISSUE SPECIFICITY: [Isoform 3]: Expressed in the brain, breast,
CC       kidney, lung, ovary, pancreas, testis, uterus, stomach and thyroid.
CC       {ECO:0000269|PubMed:14716293}.
CC   -!- TISSUE SPECIFICITY: [Isoform 4]: Expressed in the brain, breast,
CC       kidney, lung, ovary, pancreas, testis, uterus, stomach and thyroid.
CC       {ECO:0000269|PubMed:14716293}.
CC   -!- TISSUE SPECIFICITY: [Isoform 5]: Expressed in the brain, breast,
CC       kidney, lung, ovary, pancreas, testis, uterus, stomach and thyroid.
CC       {ECO:0000269|PubMed:14716293}.
CC   -!- TISSUE SPECIFICITY: [Isoform 6]: Not detected in the brain, breast,
CC       kidney, lung, ovary, pancreas, testis, uterus, stomach and thyroid.
CC       {ECO:0000269|PubMed:14716293}.
CC   -!- TISSUE SPECIFICITY: [Isoform 7]: Not detected in the brain, breast,
CC       kidney, lung, ovary, pancreas, testis, uterus, stomach and thyroid.
CC       {ECO:0000269|PubMed:14716293}.
CC   -!- DEVELOPMENTAL STAGE: Expressed in fetal brain and kidney.
CC       {ECO:0000269|PubMed:8988362}.
CC   -!- DEVELOPMENTAL STAGE: [Isoform 7]: Expressed in fetal liver.
CC       {ECO:0000269|PubMed:8988362}.
CC   -!- DISEASE: DEEAH syndrome (DEEAH) [MIM:619004]: An autosomal recessive
CC       disorder characterized by moderate to severe global developmental
CC       delay, impaired intellectual development, poor or absent speech, and
CC       endocrine, pancreatic exocrine and autonomic dysfunction, as well as
CC       hematologic abnormalities. Additional features include facial
CC       dysmorphism, seizures, undescended testes, and distal skeletal
CC       anomalies. Death in early childhood may occur.
CC       {ECO:0000269|PubMed:32761064}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Neurodevelopmental disorder with dysmorphic facies, impaired
CC       speech, and hypotonia (NEDDISH) [MIM:619005]: An autosomal recessive
CC       disorder characterized by global developmental delay, mildly to
CC       severely impaired intellectual development, poor speech and language
CC       acquisition. Some patients may have early normal development with onset
CC       of the disorder in the first years of life. More variable neurologic
CC       abnormalities include hypotonia, seizures, apnea, mild signs of
CC       autonomic or peripheral neuropathy, and autism.
CC       {ECO:0000269|PubMed:28940097, ECO:0000269|PubMed:32761064}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- MISCELLANEOUS: Overexpression of MADD activates the mitogen-activated
CC       protein (MAP) kinase extracellular signal-regulated kinase (ERK).
CC       Expression of the MADD death domain stimulates both the ERK and c-JUN
CC       N-terminal kinase MAP kinases and induces the phosphorylation of
CC       cytosolic phospholipase A2. {ECO:0000269|PubMed:9115275}.
CC   -!- SIMILARITY: Belongs to the MADD family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA20814.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U44953; AAD12154.1; -; mRNA.
DR   EMBL; U77352; AAB57735.1; -; mRNA.
DR   EMBL; AF440100; AAL40265.1; -; mRNA.
DR   EMBL; AF440101; AAL40266.1; -; mRNA.
DR   EMBL; AF440102; AAL40267.1; -; mRNA.
DR   EMBL; AF440103; AAL40268.1; -; mRNA.
DR   EMBL; AF440434; AAL35261.1; -; mRNA.
DR   EMBL; AB002356; BAA20814.2; ALT_INIT; mRNA.
DR   EMBL; AK292442; BAF85131.1; -; mRNA.
DR   EMBL; AC018410; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC090582; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471064; EAW67931.1; -; Genomic_DNA.
DR   EMBL; CH471064; EAW67932.1; -; Genomic_DNA.
DR   EMBL; BC040484; AAH40484.1; -; mRNA.
DR   CCDS; CCDS41642.1; -. [Q8WXG6-7]
DR   CCDS; CCDS44586.1; -. [Q8WXG6-3]
DR   CCDS; CCDS44587.1; -. [Q8WXG6-4]
DR   CCDS; CCDS44588.1; -. [Q8WXG6-5]
DR   CCDS; CCDS44589.1; -. [Q8WXG6-8]
DR   CCDS; CCDS44590.1; -. [Q8WXG6-6]
DR   CCDS; CCDS7930.1; -. [Q8WXG6-1]
DR   CCDS; CCDS7932.1; -. [Q8WXG6-2]
DR   RefSeq; NP_001129415.1; NM_001135943.1.
DR   RefSeq; NP_001129416.1; NM_001135944.1. [Q8WXG6-8]
DR   RefSeq; NP_003673.3; NM_003682.3. [Q8WXG6-1]
DR   RefSeq; NP_569826.2; NM_130470.2.
DR   RefSeq; NP_569827.2; NM_130471.2. [Q8WXG6-4]
DR   RefSeq; NP_569828.2; NM_130472.2. [Q8WXG6-5]
DR   RefSeq; NP_569829.2; NM_130473.2. [Q8WXG6-2]
DR   RefSeq; NP_569830.2; NM_130474.2. [Q8WXG6-6]
DR   RefSeq; NP_569831.1; NM_130475.2. [Q8WXG6-7]
DR   RefSeq; NP_569832.2; NM_130476.2. [Q8WXG6-3]
DR   RefSeq; XP_005253246.1; XM_005253189.2.
DR   RefSeq; XP_005253253.1; XM_005253196.2.
DR   RefSeq; XP_005253256.1; XM_005253199.2.
DR   RefSeq; XP_005253258.1; XM_005253201.2.
DR   RefSeq; XP_005253260.1; XM_005253203.2.
DR   RefSeq; XP_005253261.1; XM_005253204.2.
DR   RefSeq; XP_005253262.1; XM_005253205.1.
DR   AlphaFoldDB; Q8WXG6; -.
DR   BioGRID; 114136; 114.
DR   ELM; Q8WXG6; -.
DR   IntAct; Q8WXG6; 26.
DR   MINT; Q8WXG6; -.
DR   STRING; 9606.ENSP00000310933; -.
DR   GlyCosmos; Q8WXG6; 2 sites, 1 glycan.
DR   GlyGen; Q8WXG6; 2 sites, 1 O-linked glycan (2 sites).
DR   iPTMnet; Q8WXG6; -.
DR   MetOSite; Q8WXG6; -.
DR   PhosphoSitePlus; Q8WXG6; -.
DR   BioMuta; MADD; -.
DR   DMDM; 126215742; -.
DR   EPD; Q8WXG6; -.
DR   jPOST; Q8WXG6; -.
DR   MassIVE; Q8WXG6; -.
DR   MaxQB; Q8WXG6; -.
DR   PaxDb; Q8WXG6; -.
DR   PeptideAtlas; Q8WXG6; -.
DR   ProteomicsDB; 6231; -.
DR   ProteomicsDB; 75032; -. [Q8WXG6-1]
DR   ProteomicsDB; 75033; -. [Q8WXG6-2]
DR   ProteomicsDB; 75034; -. [Q8WXG6-3]
DR   ProteomicsDB; 75035; -. [Q8WXG6-4]
DR   ProteomicsDB; 75036; -. [Q8WXG6-5]
DR   ProteomicsDB; 75037; -. [Q8WXG6-6]
DR   ProteomicsDB; 75038; -. [Q8WXG6-7]
DR   Antibodypedia; 13636; 200 antibodies from 36 providers.
DR   DNASU; 8567; -.
DR   Ensembl; ENST00000311027.9; ENSP00000310933.4; ENSG00000110514.20. [Q8WXG6-1]
DR   Ensembl; ENST00000349238.7; ENSP00000304505.6; ENSG00000110514.20. [Q8WXG6-2]
DR   Ensembl; ENST00000395336.7; ENSP00000378745.3; ENSG00000110514.20. [Q8WXG6-7]
DR   Ensembl; ENST00000395344.7; ENSP00000378753.3; ENSG00000110514.20. [Q8WXG6-8]
DR   Ensembl; ENST00000402192.6; ENSP00000384287.2; ENSG00000110514.20. [Q8WXG6-3]
DR   Ensembl; ENST00000402799.5; ENSP00000385585.1; ENSG00000110514.20. [Q8WXG6-5]
DR   Ensembl; ENST00000406482.5; ENSP00000384435.1; ENSG00000110514.20. [Q8WXG6-6]
DR   Ensembl; ENST00000407859.7; ENSP00000384204.3; ENSG00000110514.20. [Q8WXG6-4]
DR   GeneID; 8567; -.
DR   KEGG; hsa:8567; -.
DR   UCSC; uc001ner.2; human. [Q8WXG6-1]
DR   AGR; HGNC:6766; -.
DR   CTD; 8567; -.
DR   DisGeNET; 8567; -.
DR   GeneCards; MADD; -.
DR   HGNC; HGNC:6766; MADD.
DR   HPA; ENSG00000110514; Tissue enhanced (retina).
DR   MalaCards; MADD; -.
DR   MIM; 603584; gene+phenotype.
DR   MIM; 619004; phenotype.
DR   MIM; 619005; phenotype.
DR   neXtProt; NX_Q8WXG6; -.
DR   OpenTargets; ENSG00000110514; -.
DR   Orphanet; 528084; Non-specific syndromic intellectual disability.
DR   PharmGKB; PA30523; -.
DR   VEuPathDB; HostDB:ENSG00000110514; -.
DR   eggNOG; KOG3570; Eukaryota.
DR   GeneTree; ENSGT00940000156718; -.
DR   HOGENOM; CLU_001270_1_0_1; -.
DR   InParanoid; Q8WXG6; -.
DR   OMA; SHIGFIY; -.
DR   PhylomeDB; Q8WXG6; -.
DR   TreeFam; TF318583; -.
DR   PathwayCommons; Q8WXG6; -.
DR   Reactome; R-HSA-5357905; Regulation of TNFR1 signaling.
DR   Reactome; R-HSA-8876198; RAB GEFs exchange GTP for GDP on RABs. [Q8WXG6-3]
DR   SignaLink; Q8WXG6; -.
DR   SIGNOR; Q8WXG6; -.
DR   BioGRID-ORCS; 8567; 12 hits in 1159 CRISPR screens.
DR   ChiTaRS; MADD; human.
DR   GeneWiki; MADD_(gene); -.
DR   GenomeRNAi; 8567; -.
DR   Pharos; Q8WXG6; Tbio.
DR   PRO; PR:Q8WXG6; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   RNAct; Q8WXG6; protein.
DR   Bgee; ENSG00000110514; Expressed in right hemisphere of cerebellum and 190 other tissues.
DR   ExpressionAtlas; Q8WXG6; baseline and differential.
DR   Genevisible; Q8WXG6; HS.
DR   GO; GO:0030424; C:axon; IEA:UniProtKB-SubCell.
DR   GO; GO:0005737; C:cytoplasm; TAS:ProtInc.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0005123; F:death receptor binding; TAS:ProtInc.
DR   GO; GO:0005085; F:guanyl-nucleotide exchange factor activity; IDA:UniProtKB.
DR   GO; GO:0030295; F:protein kinase activator activity; TAS:UniProtKB.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0097194; P:execution phase of apoptosis; IMP:UniProtKB.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IMP:UniProtKB.
DR   GO; GO:0042981; P:regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0051726; P:regulation of cell cycle; IMP:UniProtKB.
DR   GO; GO:2001236; P:regulation of extrinsic apoptotic signaling pathway; IDA:UniProtKB.
DR   GO; GO:1902041; P:regulation of extrinsic apoptotic signaling pathway via death domain receptors; IMP:UniProtKB.
DR   GO; GO:0032483; P:regulation of Rab protein signal transduction; IDA:FlyBase.
DR   Gene3D; 3.30.450.200; -; 1.
DR   Gene3D; 3.40.50.11500; -; 1.
DR   InterPro; IPR001194; cDENN_dom.
DR   InterPro; IPR005112; dDENN_dom.
DR   InterPro; IPR043153; DENN_C.
DR   InterPro; IPR039980; MADD.
DR   InterPro; IPR037516; Tripartite_DENN.
DR   InterPro; IPR005113; uDENN_dom.
DR   PANTHER; PTHR13008:SF7; MAP KINASE-ACTIVATING DEATH DOMAIN PROTEIN; 1.
DR   PANTHER; PTHR13008; MAP-KINASE ACTIVATING DEATH DOMAIN PROTEIN MADD /DENN/AEX-3 C.ELEGANS; 1.
DR   Pfam; PF02141; DENN; 1.
DR   Pfam; PF03456; uDENN; 1.
DR   SMART; SM00801; dDENN; 1.
DR   SMART; SM00799; DENN; 1.
DR   SMART; SM00800; uDENN; 1.
DR   PROSITE; PS50211; DENN; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Apoptosis; Cell membrane; Cell projection; Cytoplasm;
KW   Guanine-nucleotide releasing factor; Intellectual disability; Membrane;
KW   Phosphoprotein; Reference proteome.
FT   CHAIN           1..1647
FT                   /note="MAP kinase-activating death domain protein"
FT                   /evidence="ECO:0000250|UniProtKB:O08873"
FT                   /id="PRO_0000278138"
FT   DOMAIN          14..268
FT                   /note="uDENN"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00304"
FT   DOMAIN          289..429
FT                   /note="cDENN"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00304"
FT   DOMAIN          431..565
FT                   /note="dDENN"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00304"
FT   DOMAIN          1340..1415
FT                   /note="Death"
FT                   /evidence="ECO:0000255"
FT   REGION          108..168
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          604..636
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          678..842
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          913..941
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1051..1110
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1146..1243
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        128..156
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        689..719
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        793..808
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        817..842
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1159..1215
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         156
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         689
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O08873"
FT   MOD_RES         692
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         813
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O08873"
FT   MOD_RES         818
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         820
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         858
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         862
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         916
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         921
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         930
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O08873"
FT   MOD_RES         1059
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1061
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:O08873"
FT   MOD_RES         1066
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q80U28"
FT   MOD_RES         1110
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q80U28"
FT   MOD_RES         1237
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1239
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1270
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   VAR_SEQ         762..804
FT                   /note="Missing (in isoform 4, isoform 5, isoform 6 and
FT                   isoform 8)"
FT                   /evidence="ECO:0000303|PubMed:11577081,
FT                   ECO:0000303|PubMed:14702039, ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:8988362, ECO:0000303|PubMed:9796103"
FT                   /id="VSP_052293"
FT   VAR_SEQ         885..904
FT                   /note="Missing (in isoform 3, isoform 5, isoform 6 and
FT                   isoform 8)"
FT                   /evidence="ECO:0000303|PubMed:11577081,
FT                   ECO:0000303|PubMed:14702039, ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:8988362, ECO:0000303|PubMed:9115275,
FT                   ECO:0000303|PubMed:9796103"
FT                   /id="VSP_052294"
FT   VAR_SEQ         1121..1139
FT                   /note="ELWNKHQEVKKQKALEKQR -> G (in isoform 2, isoform 3,
FT                   isoform 4, isoform 5, isoform 6 and isoform 8)"
FT                   /evidence="ECO:0000303|PubMed:11577081,
FT                   ECO:0000303|PubMed:14702039, ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:8988362, ECO:0000303|PubMed:9115275,
FT                   ECO:0000303|PubMed:9796103"
FT                   /id="VSP_052295"
FT   VAR_SEQ         1197..1200
FT                   /note="Missing (in isoform 8)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_044848"
FT   VAR_SEQ         1201
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:8988362,
FT                   ECO:0000303|PubMed:9115275, ECO:0000303|PubMed:9796103"
FT                   /id="VSP_055676"
FT   VAR_SEQ         1291..1311
FT                   /note="Missing (in isoform 2, isoform 3, isoform 4, isoform
FT                   5, isoform 6 and isoform 8)"
FT                   /evidence="ECO:0000303|PubMed:11577081,
FT                   ECO:0000303|PubMed:14702039, ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:8988362, ECO:0000303|PubMed:9115275,
FT                   ECO:0000303|PubMed:9796103"
FT                   /id="VSP_052296"
FT   VAR_SEQ         1575..1582
FT                   /note="VFIELNHI -> FLKLKKW (in isoform 6 and isoform 7)"
FT                   /evidence="ECO:0000303|PubMed:11577081,
FT                   ECO:0000303|PubMed:9205841"
FT                   /id="VSP_052297"
FT   VAR_SEQ         1583..1647
FT                   /note="Missing (in isoform 6 and isoform 7)"
FT                   /evidence="ECO:0000303|PubMed:11577081,
FT                   ECO:0000303|PubMed:9205841"
FT                   /id="VSP_052298"
FT   VARIANT         198
FT                   /note="R -> H (in NEDDISH; unknown pathological
FT                   significance; dbSNP:rs149316791)"
FT                   /evidence="ECO:0000269|PubMed:28940097"
FT                   /id="VAR_084659"
FT   VARIANT         216..1647
FT                   /note="Missing (in DEEAH; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:32761064"
FT                   /id="VAR_084660"
FT   VARIANT         257
FT                   /note="S -> F (in DEEAH; impaired TNFA-induced activation
FT                   of the MAP kinases ERK1/2; enhanced susceptibility to
FT                   TNFA-induced apoptosis; decreased EGF internalization)"
FT                   /evidence="ECO:0000269|PubMed:32761064"
FT                   /id="VAR_084661"
FT   VARIANT         305
FT                   /note="G -> V (in DEEAH; impaired TNFA-induced activation
FT                   of the MAP kinases ERK1/2; enhanced susceptibility to
FT                   TNFA-induced apoptosis; decreased EGF internalization)"
FT                   /evidence="ECO:0000269|PubMed:32761064"
FT                   /id="VAR_084662"
FT   VARIANT         327..1647
FT                   /note="Missing (in DEEAH and NEDDISH; unknown pathological
FT                   significance; dbSNP:rs147179561)"
FT                   /evidence="ECO:0000269|PubMed:28940097,
FT                   ECO:0000269|PubMed:32761064"
FT                   /id="VAR_084663"
FT   VARIANT         346
FT                   /note="L -> P (in NEDDISH; unknown pathological
FT                   significance; dbSNP:rs1591767154)"
FT                   /evidence="ECO:0000269|PubMed:32761064"
FT                   /id="VAR_084664"
FT   VARIANT         354
FT                   /note="P -> L (in NEDDISH; impaired TNFA-induced activation
FT                   of the MAP kinases ERK1/2; enhanced susceptibility to
FT                   TNFA-induced apoptosis; decreased EGF internalization;
FT                   dbSNP:rs370382902)"
FT                   /evidence="ECO:0000269|PubMed:32761064"
FT                   /id="VAR_084665"
FT   VARIANT         372
FT                   /note="P -> L (in DEEAH; unknown pathological significance;
FT                   dbSNP:rs147713337)"
FT                   /evidence="ECO:0000269|PubMed:32761064"
FT                   /id="VAR_084666"
FT   VARIANT         696
FT                   /note="P -> T (in dbSNP:rs17854007)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_030666"
FT   VARIANT         751
FT                   /note="V -> M (in dbSNP:rs1051006)"
FT                   /evidence="ECO:0000269|PubMed:9115275"
FT                   /id="VAR_030667"
FT   VARIANT         765
FT                   /note="R -> Q (in dbSNP:rs3736101)"
FT                   /id="VAR_051148"
FT   VARIANT         945
FT                   /note="L -> P (in NEDDISH; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:32761064"
FT                   /id="VAR_084667"
FT   VARIANT         968
FT                   /note="R -> G (in dbSNP:rs17854008)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_030668"
FT   VARIANT         1040
FT                   /note="L -> F (in dbSNP:rs17854009)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_030669"
FT   VARIANT         1040
FT                   /note="L -> R (in DEEAH; impaired TNFA-induced activation
FT                   of the MAP kinases ERK1/2; enhanced susceptibility to
FT                   TNFA-induced apoptosis; decreased EGF internalization)"
FT                   /evidence="ECO:0000269|PubMed:28940097,
FT                   ECO:0000269|PubMed:32761064"
FT                   /id="VAR_084668"
FT   VARIANT         1213..1647
FT                   /note="Missing (in NEDDISH; impaired TNFA-induced
FT                   activation of the MAP kinases ERK1/2; enhanced
FT                   susceptibility to TNFA-induced apoptosis; decreased EGF
FT                   internalization)"
FT                   /evidence="ECO:0000269|PubMed:32761064"
FT                   /id="VAR_084669"
FT   VARIANT         1283
FT                   /note="Y -> S (in NEDDISH; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:32761064"
FT                   /id="VAR_084670"
FT   VARIANT         1318
FT                   /note="W -> R (in NEDDISH; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:32761064"
FT                   /id="VAR_084671"
FT   VARIANT         1431..1647
FT                   /note="Missing (in DEEAH; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:32761064"
FT                   /id="VAR_084672"
FT   VARIANT         1518
FT                   /note="L -> P (in dbSNP:rs34534575)"
FT                   /id="VAR_051149"
FT   VARIANT         1532..1647
FT                   /note="Missing (in NEDDISH; unknown pathological
FT                   significance; dbSNP:rs971864929)"
FT                   /evidence="ECO:0000269|PubMed:32761064"
FT                   /id="VAR_084673"
FT   CONFLICT        108
FT                   /note="E -> G (in Ref. 4;
FT                   AAL40265/AAL40266/AAL40267/AAL40268/AAL35261)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        145
FT                   /note="L -> F (in Ref. 4;
FT                   AAL40265/AAL40266/AAL40267/AAL40268/AAL35261)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        205
FT                   /note="E -> G (in Ref. 6; BAF85131)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        312
FT                   /note="V -> L (in Ref. 4;
FT                   AAL40265/AAL40266/AAL40267/AAL40268/AAL35261)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        482
FT                   /note="V -> A (in Ref. 4;
FT                   AAL40265/AAL40266/AAL40267/AAL40268/AAL35261)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        500
FT                   /note="A -> V (in Ref. 6; BAF85131)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1262
FT                   /note="S -> C (in Ref. 4;
FT                   AAL40265/AAL40266/AAL40267/AAL40268/AAL35261)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1592
FT                   /note="F -> S (in Ref. 6; BAF85131)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1639
FT                   /note="R -> G (in Ref. 6; BAF85131)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   1647 AA;  183303 MW;  2CA9A3519269757E CRC64;
     MVQKKKFCPR LLDYLVIVGA RHPSSDSVAQ TPELLRRYPL EDHTEFPLPP DVVFFCQPEG
     CLSVRQRRMS LRDDTSFVFT LTDKDTGVTR YGICVNFYRS FQKRISKEKG EGGAGSRGKE
     GTHATCASEE GGTESSESGS SLQPLSADST PDVNQSPRGK RRAKAGSRSR NSTLTSLCVL
     SHYPFFSTFR ECLYTLKRLV DCCSERLLGK KLGIPRGVQR DTMWRIFTGS LLVEEKSSAL
     LHDLREIEAW IYRLLRSPVP VSGQKRVDIE VLPQELQPAL TFALPDPSRF TLVDFPLHLP
     LELLGVDACL QVLTCILLEH KVVLQSRDYN ALSMSVMAFV AMIYPLEYMF PVIPLLPTCM
     ASAEQLLLAP TPYIIGVPAS FFLYKLDFKM PDDVWLVDLD SNRVIAPTNA EVLPILPEPE
     SLELKKHLKQ ALASMSLNTQ PILNLEKFHE GQEIPLLLGR PSNDLQSTPS TEFNPLIYGN
     DVDSVDVATR VAMVRFFNSA NVLQGFQMHT RTLRLFPRPV VAFQAGSFLA SRPRQTPFAE
     KLARTQAVEY FGEWILNPTN YAFQRIHNNM FDPALIGDKP KWYAHQLQPI HYRVYDSNSQ
     LAEALSVPPE RDSDSEPTDD SGSDSMDYDD SSSSYSSLGD FVSEMMKCDI NGDTPNVDPL
     THAALGDASE VEIDELQNQK EAEEPGPDSE NSQENPPLRS SSSTTASSSP STVIHGANSE
     PADSTEMDDK AAVGVSKPLP SVPPSIGKSN VDRRQAEIGE GSVRRRIYDN PYFEPQYGFP
     PEEDEDEQGE SYTPRFSQHV SGNRAQKLLR PNSLRLASDS DAESDSRASS PNSTVSNTST
     EGFGGIMSFA SSLYRNHSTS FSLSNLTLPT KGAREKATPF PSLKVFGLNT LMEIVTEAGP
     GSGEGNRRAL VDQKSSVIKH SPTVKREPPS PQGRSSNSSE NQQFLKEVVH SVLDGQGVGW
     LNMKKVRRLL ESEQLRVFVL SKLNRMVQSE DDARQDIIPD VEISRKVYKG MLDLLKCTVL
     SLEQSYAHAG LGGMASIFGL LEIAQTHYYS KEPDKRKRSP TESVNTPVGK DPGLAGRGDP
     KAMAQLRVPQ LGPRAPSATG KGPKELDTRS LKEENFIASI ELWNKHQEVK KQKALEKQRP
     EVIKPVFDLG ETEEKKSQIS ADSGVSLTSS SQRTDQDSVI GVSPAVMIRS SSQDSEVSTV
     VSNSSGETLG ADSDLSSNAG DGPGGEGSVH LASSRGTLSD SEIETNSATS TIFGKAHSLK
     PSIKEKLAGS PIRTSEDVSQ RVYLYEGLLG RDKGSMWDQL EDAAMETFSI SKERSTLWDQ
     MQFWEDAFLD AVMLEREGMG MDQGPQEMID RYLSLGEHDR KRLEDDEDRL LATLLHNLIS
     YMLLMKVNKN DIRKKVRRLM GKSHIGLVYS QQINEVLDQL ANLNGRDLSI WSSGSRHMKK
     QTFVVHAGTD TNGDIFFMEV CDDCVVLRSN IGTVYERWWY EKLINMTYCP KTKVLCLWRR
     NGSETQLNKF YTKKCRELYY CVKDSMERAA ARQQSIKPGP ELGGEFPVQD LKTGEGGLLQ
     VTLEGINLKF MHNQVFIELN HIKKCNTVRG VFVLEEFVPE IKEVVSHKYK TPMAHEICYS
     VLCLFSYVAA VHSSEEDLRT PPRPVSS
//
